Colorectal cancer in 2013: Towards improved drugs, combinations and patient selection

Nature Reviews Clinical Oncology

Volumn 11, Issue 2, 2014, Pages 79-80

  Schmoll, Hans Joachim ^a   Stein, Alexander ^b  

^a MARTIN LUTHER UNIVERSITY HALLE WITTENBERG   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; HUMANS; PATIENT SELECTION; TIME FACTORS;

EID: 84895904994     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2013.254     Document Type: Review

References (9)

1. Falcone, A. et al. FOLFOXIRI/bevacizumab (bev) versus FOLFIRI/bev as first-line treatment in unresectable metastatic colorectal cancer (mCRC) patients (pts): Results of the phase III TRI BE trial by GONO group [abstract]. J. Clin. Oncol. 31 (Suppl.), a3505 (2013).
2. Douillard, J. Y. et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N. Engl. J. Med. 369, 1023-1034 (2013).
3. Schwartzberg, L. et al. Analysis of KRAS/NRAS mutations in PEAK: A randomized phase II study of FOLFOX6 plus panitumumab (pmab) or bevacizumab (bev) as first-line treatment (tx) for wild-type (WT) KRA S (exon 2) metastatic colorectal cancer (mCRC) [abstract]. J. Clin. Oncol. 31 (Suppl.), a3631 (2013).
4. Stintzing, S. et al. Analysis of KRAS/NRAS and BRAF mutations in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients [abstract]. Eur. J. Cancer 47, LBA17(2013).
5. Bennouna, J. et al. Continuation of bev acizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase III trial. Lancet Oncol. 14, 29-37 (2013).
6. Carrato, A. et al. Fluorouracil, leucovorin, and irinot ecan plus either sunitinib or placebo in metastatic colorectal cancer: A randomized, phase III trial. J. Clin. Oncol. 31, 1341-1347 (2013).
7. Schmoll, H. J. et al. Cediranib with mFOLFOX6 versus bevac izumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: A double-blind, randomized phase III study (HORIZON III). J.Clin. Oncol. 30, 3588-3595 (2012).
8. Grothey, A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): An international, multicentre, randomised, placebo-controlled, phase III trial. Lancet 381, 303-312 (2013).
9. Sadanandam, A. et al. A colorectal cancer classification system that associates cellular phenotype and responses to therapy. Nat. Med. 19, 619-625 (2013).